

Appendix 1A: List of the Three-City study coded substances that required renal dose adjustment and recommended eGFR threshold in mL/min/1.73 m² classified by WHO-Anatomical Therapeutic Chemical (ATC) code

ATC code	Substance or substance class requiring renal dose adjustment	eGFR threshold	ATC code	Substance or substance class requiring renal dose adjustment	eGFR threshold
A02BA01	cimetidine	<50	J01DC04	cefaclor	<30
A02BA02	ranitidine	<50	J01DC07	cefotiam	<30
A02BA03	famotidine	<30	J01DD08	cefixime	<30
A02BA04	nizatidine	<50	J01DD13	cefepodoxime	<60
A03FA02	Cisapride	<60	J01E	<i>Sulfonamides and trimethoprim</i>	<30
A03FA03	domperidone	<60	J01MA	<i>Fluoroquinolones</i>	<30
C01AA05	digoxin	<60	J01MA12	levofloxacin	<60
C01BA03	disopyramide	<60	J01MB02	nalidixic acid	<15
C01BC04	flecainide	<30	J01XX01	fosfomycin	<60
C02AB	methylodopa	<50	J05AB01	aciclovir	<50
C02CA02	indoramin	30 - 60	J05AB11	valaciclovir	<50
C02AC05	moxonidine	<60	J05AF02	didanosine	<60
C02AC06	rilmenidine	<80	J05AF04	stavudine	<60
C03CA	<i>Sulfonamides, plain</i>	<30	L01BA01	methotrexate	<60
C03DB01	amiloride	30-60	M01AX21	diacerein	<30
C04AX20	bufloamedil	<40	M04AA01	allopurinol	<80
C07AA07	sotalol	<30	M05BA	<i>Bisphosphonates</i>	<60
C07AA12	nadolol	<30	N02AA01	morphine	<30
C07AA15	carteolol	<60	N02AB03	fentanyl	30-60
C07AB	<i>Beta blocking agents, selective</i>	<30	N02AX02	tramadol	<60
C09AA01	captopril	<40	N02BA01/51/71	aspirin	<60
C09AA02	enalapril	<30	N02BA10	benorilate	<60
C09AA04	perindopril	<60	N02BE01/51/71	acetaminophen	<50
C09AA05	ramipril	<30	N02BE05	propacetamol	<50
C09AA06	quinapril	<60	N02CC02	naratriptan	<60
C09AA07	benazepril	<30	N03AA02	phenobarbital	<60
C09AA08	cilazapril	<30	N03AA03	primidone	<30
C09AA10	trandolapril	<30	N03AG04	vigabatrin	<60
C09AA13	moexipril	<40	N03AX12	gabapentin	<60
C09AA16	imidapril	<25	N04BA02	levodopa and decarboxylase inhibitor	<60
C10AA01	simvastatin	<60	N04BB01	amantadine	<60
C10AB02	bezafibrate	<60	N05AX08	risperidone	<60
C10AB05	fenofibrate	<60	N05BA08	bromazepam	<90
G04BE03	sildenafil	<30	N06AX16	venlafaxine	<30
J01CA01	ampicillin	<30	N06AX17	milnacipran	<60
J01CA02	pivampicillin	<30	N06BX17	adafinil	<60
J01CA04	amoxicillin	<30	P01BA01	chloroquine	<80
J01DC02	cefuroxime	<30	R03CC12	bambuterol	<60

Appendix 1B: List of the Three-City study coded substances that were contraindicated and recommended eGFR thresholds in mL/min/1.73 m² classified by WHO-Anatomical Therapeutic Chemical (ATC) code

ATC code	Substance or substance class with renal contraindication	eGFR threshold
A02AB	<i>Antacids, Aluminium compounds</i>	<30
A02X	<i>Antacids, other combinations</i>	<30
A07EC03	olsalazine	<30
A10BA02	metformin	<60
A10BB01	glibenclamide	<30
A10BB06	carbutamide	<30
A10BB07	glipizide	<30
A10BB09	gliclazide	<30
A10BB12	glimepiride	<30
A10BF01	acarbose	<30
A10BF02	miglitol	<25
B01AA	<i>Vitamin K antagonists</i>	<30
B01AB04	dalteparin	<30
B01AB05	enoxaparin	<30
B01AB06	nadroparin	<30
B02AA02	tranexamic acid	<30
C02AC05	monoxidine	<30
C02L	<i>Antihypertensives and diuretics in combination</i>	<30
C03A	<i>Low-ceiling diuretics, thiazides</i>	<30
C03B	<i>Low-ceiling diuretics, excl. thiazides</i>	<30
C03D	<i>potassium-sparing agents</i>	<30
C03E	<i>diuretics and potassium-sparing agents in combination</i>	<30
C07B	<i>Beta blocking agents and thiazides</i>	<30
C07D	<i>Beta blocking agents, thiazides and other diuretics</i>	<30
C09BA	<i>ACE inhibitors and diuretics</i>	<30
C09DA	<i>Angiotensin II antagonists and diuretics</i>	<30
C10AA07	rosuvastatin	<30
C10AX03	tiadenol	<80
G02CB04	quinagolide	<60
G03AA06	norgestrel and estrogen	<60
G03BA03	testosterone	<60
G04BA	<i>Other urologicals, incl. antispasmodics, acidifiers</i>	<30
G04BE04	yohimbine	<30
H01	<i>Pituitary and hypothalamic hormones and analogues</i>	<30
M01AE02	naproxen	<30
M01AH	Coxibs	<30
M01AX22	Morniflumate	<30
M04AB03	benzbromarone	<80
M04AC01	colchicine	<30
M05BA	biphosphonates	<30
N06AX01	oxitriptan	<30
none	prazinil	<30
R06AE07	cetirizine	<60
S01EC	<i>Antiglaucoma preparations and miotics, carbonic anhydrase inhibitors</i>	<30